AD Elias

750 total citations
19 papers, 556 citations indexed

About

AD Elias is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, AD Elias has authored 19 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Hematology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in AD Elias's work include Hematopoietic Stem Cell Transplantation (7 papers), Advanced Breast Cancer Therapies (5 papers) and Neutropenia and Cancer Infections (4 papers). AD Elias is often cited by papers focused on Hematopoietic Stem Cell Transplantation (7 papers), Advanced Breast Cancer Therapies (5 papers) and Neutropenia and Cancer Infections (4 papers). AD Elias collaborates with scholars based in United States, Chile and Italy. AD Elias's co-authors include KC Anderson, Lois Ayash, Gary N. Schwartz, I Tepler, Stephen Pap, C Lynch, M Hunt, Rosemary Mazanet, Catherine Wheeler and L.N. Daniel and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

AD Elias

19 papers receiving 536 citations

Peers

AD Elias

HEMAT

ONCOL

GENET

MB

GENET

A Ferrant Belgium

Zhengming Jin China

Sharon Tindle United States

Masaaki Kumagai Japan

JH Kersey United States

Ž Pavletić United States

Alexey Maschan Russia

P. Dyson Australia

D Thorp Australia

PI Warkentin United States

A Ferrant Belgium

AD Elias

342 ×1.0

HEMAT

175 ×0.6

ONCOL

189 ×1.7

GENET

110 ×1.1

MB

71 ×0.8

GENET

Citations per year, relative to AD Elias AD Elias (= 1×) peers A Ferrant

Countries citing papers authored by AD Elias

Since Specialization

Citations

This map shows the geographic impact of AD Elias's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AD Elias with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AD Elias more than expected).

Fields of papers citing papers by AD Elias

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by AD Elias. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AD Elias. The network helps show where AD Elias may publish in the future.

Co-authorship network of co-authors of AD Elias

This figure shows the co-authorship network connecting the top 25 collaborators of AD Elias. A scholar is included among the top collaborators of AD Elias based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AD Elias. AD Elias is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Gucalp, Ayca, Aditya Bardia, Nashat Gabrail, et al.. (2017). Abstract P2-08-04: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC). Cancer Research. 77(4_Supplement). P2–8. 4 indexed citations

2.

Elias, AD, et al.. (2016). Abstract P1-16-05: MDV3100-08: A phase 1 study evaluating the safety and pharmacokinetics of enzalutamide plus fulvestrant in women with advanced hormone receptor-positive breast cancer. Cancer Research. 76(4_Supplement). P1–16. 7 indexed citations

3.

Traina, Tiffany A., Denise A. Yardley, Manish R. Patel, et al.. (2014). A Phase 1 Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide Alone or Combined with an Aromatase Inhibitor in Women with Advanced Breast Cancer. Annals of Oncology. 25. i4–i4. 3 indexed citations

4.

Bernales, Sebastián, et al.. (2012). Abstract P2-14-02: Preclinical Evaluation of Enzalutamide in Breast Cancer Models. Cancer Research. 72(24_Supplement). P2–14. 2 indexed citations

5.

Lu, Dan, et al.. (2011). P1-12-07: Pharmacokinetics (PK) of Trastuzumab Emtansine and Paclitaxel or Docetaxel in Patients with HER2−Positive MBC Previously Treated with a Trastuzumab-Containing Regimen.. Cancer Research. 71(24_Supplement). P1–12. 3 indexed citations

6.

Curigliano, Giuseppe, Xavier Pivot, Javier Cortés, et al.. (2010). Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer. Cancer Research. 70(24_Supplement). P6–12. 7 indexed citations

7.

Kabos, Peter, et al.. (2009). The chemoresistant population of luminal subtype human breast cancer cells expresses a basal phenotype.. Cancer Research. 69(2_Supplement). 42–42. 5 indexed citations

8.

Conté, Pierfranco, Mario Campone, P. Pronzato, et al.. (2009). Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. Journal of Clinical Oncology. 27(15_suppl). 1081–1081. 18 indexed citations

9.

Avigan, David, Robin Joyce, AD Elias, et al.. (2000). Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transplantation. 26(2). 169–176. 25 indexed citations

10.

Elias, AD, Catherine Wheeler, Lois Ayash, et al.. (1998). Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.. PubMed. 4(6). 1443–9. 4 indexed citations

11.

Shapiro, Charles L., Lois Ayash, Iain J. Webb, et al.. (1997). Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.. Journal of Clinical Oncology. 15(2). 674–683. 24 indexed citations

12.

Webb, Iain J., AD Elias, Lois Ayash, et al.. (1996). Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte‐colony‐stimulating factor: implications for yield of hematopoietic progenitor cell collections. Transfusion. 36(2). 160–167. 18 indexed citations

13.

Chen, L, Michael A. Pulsipher, D Chen, et al.. (1996). Selective transgene expression for detection and elimination of contaminating carcinoma cells in hematopoietic stem cell sources.. Journal of Clinical Investigation. 98(11). 2539–2548. 56 indexed citations

14.

Webb, Iain J., F Coral, J. W. Andersen, et al.. (1996). Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion. 36(9). 782–788. 64 indexed citations

15.

Churchill, W. H., Colin A. Sieff, Lawrence N. Shulman, et al.. (1995). The collection and evaluation of peripheral blood progenitor cells sufficient for repetitive cycles of high‐dose chemotherapy support. Transfusion. 35(10). 837–844. 7 indexed citations

16.

Elias, AD, Lois Ayash, KC Anderson, et al.. (1992). Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 79(11). 3036–3044. 9 indexed citations

17.

Elias, AD, Lois Ayash, KC Anderson, et al.. (1992). Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 79(11). 3036–3044. 220 indexed citations

18.

Daniel, L.N., et al.. (1990). Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase [see comments]. Blood. 75(10). 2035–2041. 36 indexed citations

19.

Daniel, L.N., et al.. (1990). Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase [see comments]. Blood. 75(10). 2035–2041. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact